Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:4074
Name pancreatic adenocarcinoma
Definition A pancreatic carcinoma that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF mutant Trametinib pancreatic adenocarcinoma sensitive detail...
BRAF V600E TP53 C176R Dabrafenib + Trametinib pancreatic adenocarcinoma predicted - sensitive detail...
MLH1 negative Pembrolizumab pancreatic adenocarcinoma sensitive detail...
MSH6 negative Pembrolizumab pancreatic adenocarcinoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib pancreatic adenocarcinoma sensitive detail...
RET fusion Selpercatinib pancreatic adenocarcinoma sensitive detail...
MLH1 negative Dostarlimab-gxly pancreatic adenocarcinoma sensitive detail...
MSH6 negative Dostarlimab-gxly pancreatic adenocarcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00602602 Phase II Bevacizumab + Fluorouracil + Oxaliplatin Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Gemcitabine Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer Completed USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT01013649 Phase II Erlotinib + Gemcitabine Gemcitabine Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Active, not recruiting USA | ISR | CAN | BEL 0
NCT01088815 Phase II Gemcitabine + Nab-paclitaxel + Vismodegib Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Completed USA 0
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Completed USA | NLD | ITA | FRA | ESP | DEU | CAN 0
NCT01383538 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Saridegib FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma Completed USA 0
NCT01420874 Phase I EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Completed USA 0
NCT01431794 Phase Ib/II Gemcitabine + Nab-paclitaxel + Sonidegib Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma Terminated USA 0
NCT01473940 Phase I Gemcitabine + Ipilimumab Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT01485744 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Sonidegib LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer Completed USA 0
NCT01488552 Phase Ib/II Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Metformin Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Completed USA 0
NCT01489865 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Veliparib ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer Unknown status USA 0
NCT01506973 Phase Ib/II Hydroxychloroquine Gemcitabine A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer Completed USA 0
NCT01555489 Phase II Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca Terminated USA 0
NCT01562899 Phase II Binimetinib + Ganitumab A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 0
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS 0
NCT01585805 Phase II Veliparib Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Active, not recruiting USA | ISR | CAN 0
NCT01586611 Phase III Gemcitabine Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status CAN 0
NCT01652976 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Dasatinib Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma Completed USA 0
NCT01660971 Phase I Dasatinib + Erlotinib + Gemcitabine Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Active, not recruiting USA 0
NCT01666730 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Metformin Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Completed USA 0
NCT01683422 Phase II Capecitabine + Erlotinib + Gemcitabine Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer Terminated USA 0
NCT01764477 Phase I Gemcitabine + PRI-724 Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma Completed USA 0
NCT01783171 Phase I Dinaciclib + MK2206 Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery Completed USA | CAN 0
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT01804530 Phase I PLX7486 Gemcitabine + Nab-paclitaxel Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors Terminated USA 0
NCT01825603 Phase I ADH-1 + Cisplatin + Gemcitabine ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Completed USA 0
NCT01858883 Phase I Nab-paclitaxel Filgrastim Itacitinib Gemcitabine Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors Completed USA 0
NCT01896869 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Ipilimumab A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer Completed USA 0
NCT01908478 Phase I Veliparib Gemcitabine A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer Completed USA 0
NCT01921751 Phase II Gemcitabine + Nab-paclitaxel Capecitabine High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Terminated USA 0
NCT01924260 Phase I Alisertib + Gemcitabine Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Completed USA 0
NCT01956812 Phase III Yttrium Y-90 clivatuzumab tetraxetan Gemcitabine Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1) Terminated USA | POL | ISR | FRA | ESP | CAN | BEL | AUT 0
NCT01959672 Phase II Nelfinavir Oregovomab Fluorouracil + Leucovorin Gemcitabine Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer Completed USA 0
NCT02004262 Phase II Irinotecan Erlotinib Cyclophosphamide Capecitabine + Fluorouracil + Gemcitabine Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Completed USA | CAN 0
NCT02005315 Phase I Gemcitabine + Nab-paclitaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer Completed USA 0
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02037230 Phase Ib/II Adavosertib + Gemcitabine Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas Completed USA 0
NCT02048384 Phase Ib/II Metformin + Sirolimus Metformin A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer Completed USA 0
NCT02077881 Phase Ib/II Indoximod Gemcitabine + Nab-paclitaxel Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Completed USA 0
NCT02080260 Phase II Regorafenib A Study of Regorafenib in Advanced Pancreatic Cancer Patients Completed USA 0
NCT02117479 Phase III Ruxolitinib Capecitabine Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) Terminated USA | NZL | ITA | GBR | ESP | DEU | CAN | BEL | AUS 3
NCT02119663 Phase III Capecitabine Capecitabine + Ruxolitinib A Study of Ruxolitinib in Pancreatic Cancer Patients Terminated USA | SWE | NLD | ISR | IRL | FRA | DNK | CHE | AUT 5
NCT02138383 Phase I Enzalutamide Nab-paclitaxel Gemcitabine Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer Completed USA 0
NCT02153450 Phase I Metformin Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Completed USA 0
NCT02155088 Phase I Alpelisib + Gemcitabine + Nab-paclitaxel BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer Completed USA 0
NCT02178436 Phase Ib/II Gemcitabine + Nab-paclitaxel + Selinexor Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer Completed USA 0
NCT02184195 Phase III Olaparib Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO) Completed USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | AUS 1
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Terminated USA | FRA | ESP | CAN 1
NCT02194829 Phase Ib/II Paclitaxel Gemcitabine Adavosertib Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT02227940 Phase I Ceritinib + Gemcitabine + Nab-paclitaxel Ceritinib + Cisplatin + Gemcitabine Ceritinib + Gemcitabine Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer Completed USA 0
NCT02231723 Phase I Gemcitabine + Nab-paclitaxel + Napabucasin A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed USA 0
NCT02243371 Phase II GVAX pancreatic cancer vaccine CRS-207 Cyclophosphamide GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab Completed USA 0
NCT02244489 Phase I Capecitabine Oxaliplatin Momelotinib Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma Terminated USA 0
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed USA 0
NCT02311361 Phase I Durvalumab Tremelimumab Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Completed USA 0
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated USA 0
NCT02336087 Phase I Gemcitabine + Metformin + Nab-paclitaxel Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting USA 0
NCT02340117 Phase II SGT-53 Gemcitabine + Nab-paclitaxel Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer Unknown status USA 0
NCT02349867 Phase I Gemcitabine + Nab-paclitaxel + Sorafenib + Vorinostat Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients Completed USA 0
NCT02383433 Phase II Gemcitabine + Regorafenib Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer Terminated USA 0
NCT02399137 Phase II Nab-paclitaxel Gemcitabine MM-141 A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer Completed USA | POL | GBR | ESP | DEU | CAN 0
NCT02403271 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed USA 0
NCT02428270 Phase II GSK2256098 + Trametinib A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer Completed CAN 0
NCT02436668 Phase II Gemcitabine + Nab-paclitaxel Ibrutinib Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Completed USA | ITA | GBR | FRA | ESP | DEU | BEL 1
NCT02446093 Phase II AdV-tk + Valacyclovir Acyclovir + AdV-tk Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (PaTK02) Active, not recruiting USA 1
NCT02451982 Phase Ib/II Nivolumab Cyclophosphamide + GVAX pancreatic cancer vaccine Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer Recruiting USA 0
NCT02472977 Phase Ib/II Nivolumab Ulocuplumab Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors Terminated USA | FIN 0
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02562898 Phase Ib/II Gemcitabine + Ibrutinib + Paclitaxel Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Completed USA 0
NCT02570711 Phase II Acalabrutinib Gemcitabine + Nab-paclitaxel Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer Terminated USA 0
NCT02574663 Phase I Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Completed USA 0
NCT02575508 Phase Ib/II Fluorouracil + Infigratinib + Irinotecan + Oxaliplatin Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Withdrawn USA 0
NCT02608229 Phase I Gemcitabine + Nab-paclitaxel + Ulixertinib BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer Terminated USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | CHE 0
NCT02620423 Phase I Gemcitabine Fluorouracil Irinotecan Pelareorep Leucovorin Pembrolizumab Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma Completed USA 0
NCT02620800 Phase Ib/II Bevacizumab + Fluorouracil + Leucovorin + Nab-paclitaxel + Oxaliplatin Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer Completed USA 0
NCT02620865 Phase Ib/II Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed USA 0
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Completed USA 0
NCT02648282 Phase II Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer Completed USA 0
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated USA 0
NCT02650804 Phase II BPM 31510 BPM 31510 + Gemcitabine BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients Completed USA | GBR 0
NCT02651727 Phase I Gemcitabine + Nab-paclitaxel + VS-4718 Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects Terminated USA 0
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA | NZL | GBR | FRA | ESP | AUS 0
NCT02675946 Phase I CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Unknown status USA 1
NCT02677038 Phase II Olaparib Olaparib in Treating Patients With Stage IV Pancreatic Cancer Completed USA 0
NCT02703571 Phase Ib/II Ribociclib + Trametinib Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Terminated USA | NLD | ESP | DEU | CAN | BEL | AUS 0
NCT02734160 Phase I Durvalumab + Galunisertib A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer Completed USA | ITA | FRA | ESP 1
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | NLD | FRA | ESP | BEL | AUS 0
NCT02826486 Phase II BKT140 + Pembrolizumab BKT140 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT) Completed USA | ISR | ESP 1
NCT02847000 Phase 0 Decitabine + Tetrahydrouridine p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer Completed USA 0
NCT02868632 Phase I Tremelimumab Durvalumab + Tremelimumab Durvalumab Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer Withdrawn USA 0
NCT02890355 Phase II Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Veliparib FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting USA 0
NCT02902484 Phase Ib/II Gemcitabine + Nab-paclitaxel + Nintedanib Nintedanib Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer Terminated USA 0
NCT02907099 Phase II BKT140 + Pembrolizumab Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer Completed USA 0
NCT02908451 Phase I AbGn-107 A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer Terminated USA 1
NCT02923921 Phase III Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin Fluorouracil + Leucovorin + Oxaliplatin Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer Completed USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 2
NCT02985125 Phase Ib/II Everolimus + Ribociclib LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy Unknown status USA 0
NCT03006302 Phase II CRS-207 + Epacadostat + Pembrolizumab CRS-207 + Cyclophosphamide + Epacadostat + GVAX pancreatic cancer vaccine + Pembrolizumab Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer Completed USA 0
NCT03086369 Phase Ib/II Gemcitabine + Nab-paclitaxel + Olaratumab Gemcitabine + Nab-paclitaxel A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Completed USA | ESP | DEU 0
NCT03086642 Phase I Talimogene laherparepvec Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer Completed USA 0
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Completed USA 0
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Completed USA | ITA | FRA | ESP | DEU | CHE | CAN | AUS 1
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS 2
NCT03104439 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Recruiting USA 0
NCT03122106 Phase I Personalized cancer vaccine Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Terminated USA 0
NCT03126435 Phase III EndoTAG-1 + Gemcitabine Gemcitabine EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment Completed USA | ISR | HUN | FRA 3
NCT03127124 Phase Ib/II Bevacizumab + Fluorouracil + Leucovorin + NANT-008 + Oxaliplatin QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer Withdrawn USA 0
NCT03140670 Phase II Rucaparib Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Terminated USA 0
NCT03153410 Phase I Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Completed USA 0
NCT03190265 Phase II CRS-207 + Ipilimumab + Nivolumab CRS-207 + Cyclophosphamide + GVAX pancreatic cancer vaccine + Ipilimumab + Nivolumab Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer Completed USA 0
NCT03192462 Phase Ib/II MultiTAA-specific T cells TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (TACTOPS) Active, not recruiting USA 0
NCT03213626 Phase II Cabozantinib + Erlotinib Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma Terminated USA 0
NCT03214250 Phase Ib/II Gemcitabine + Nab-paclitaxel + Nivolumab Gemcitabine + Nab-paclitaxel + Sotigalimab Gemcitabine + Nab-paclitaxel + Nivolumab + Sotigalimab Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma Completed USA 0
NCT03245541 Phase Ib/II Durvalumab Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad) Active, not recruiting USA 0
NCT03250273 Phase II Entinostat + Nivolumab A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Completed USA 0
NCT03261947 Phase II Simurosertib A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Completed USA 1
NCT03269526 Phase Ib/II EGFRBi-armed autologous activated T cells BATs Treatment for Pancreatic Cancer, Phase Ib/II Active, not recruiting USA 0
NCT03277209 Phase I Plerixafor To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas Terminated USA | GBR 0
NCT03281382 Phase I Ad5-yCD-mutTKSR39rep-hIL12 Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer Completed USA 0
NCT03310632 Phase Ib/II Antroquinonol Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer Active, not recruiting USA 2
NCT03316599 Phase I Ficlatuzumab + Gemcitabine + Nab-paclitaxel Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer Completed USA 0
NCT03323944 Phase I HuCART-meso cells CAR T Cell Immunotherapy for Pancreatic Cancer Recruiting USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03331562 Phase II Pembrolizumab Paricalcitol + Pembrolizumab A SU2C Catalyst Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Completed USA 0
NCT03336216 Phase II Cabiralizumab + Gemcitabine + Nab-paclitaxel + Nivolumab Cabiralizumab + Nivolumab Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Cabiralizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer Completed USA | ITA | GBR | ESP | DNK | DEU | CHE | CAN 3
NCT03337087 Phase Ib/II Fluorouracil + Leucovorin + Liposomal irinotecan + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Active, not recruiting USA 0
NCT03344172 Phase II Avelumab + Gemcitabine + Hydroxychloroquine + Nab-paclitaxel Gemcitabine + Hydroxychloroquine + Nab-paclitaxel Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer (17-134) Terminated USA 0
NCT03368963 Phase Ib/II Liposomal irinotecan + Trifluridine-tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting USA 0
NCT03373188 Phase I Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Completed USA 0
NCT03374852 Phase II CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer Withdrawn 0
NCT03376659 Phase Ib/II Capecitabine + CV301 + Durvalumab Bevacizumab + Capecitabine + CV301 + Durvalumab Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Terminated USA 0
NCT03387098 Phase Ib/II GI-4000 Leucovorin Nab-paclitaxel Bevacizumab Avelumab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 Oxaliplatin Aldoxorubicin Capecitabine Cyclophosphamide QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Terminated USA 0
NCT03403049 Phase I Cisplatin + Gemcitabine Capecitabine + Gemcitabine Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer Completed USA 1
NCT03404960 Phase Ib/II Ipilimumab + Niraparib Niraparib + Nivolumab Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax) Completed USA 0
NCT03410030 Phase Ib/II Cisplatin + Gemcitabine + Nab-paclitaxel + Vitamin C Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (AA NABPLAGEM) Completed USA 0
NCT03432676 Phase II Epacadostat + Pembrolizumab Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) Withdrawn 0
NCT03451773 Phase Ib/II Bintrafusp alfa + Gemcitabine M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas Terminated USA 0
NCT03490760 Phase II Durvalumab Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas Terminated USA 0
NCT03504423 Phase III CPI-613 CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas Completed USA | ISR | FRA | DEU | BEL 1
NCT03507452 Phase I BAY2287411 First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin Completed USA | SWE | NLD | GBR | FIN 0
NCT03512756 Phase II Methoxsalen + Phenytoin + Sirolimus + SM88 Gemcitabine Fluorouracil Capecitabine A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Terminated USA 0
NCT03519308 Phase I Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol Gemcitabine + Nab-paclitaxel + Nivolumab A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer Terminated USA 0
NCT03553004 Phase II Niraparib Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial Active, not recruiting USA 0
NCT03563144 Phase II Gemcitabine Gemcitabine + Nab-paclitaxel Aldoxorubicin + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin QUILT-3.088: NANT Pancreatic Cancer Vaccine Withdrawn USA 0
NCT03563248 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Nivolumab + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer Active, not recruiting USA 0
NCT03586869 Phase Ib/II Aldoxorubicin + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin QUILT-3.080: NANT Pancreatic Cancer Vaccine Terminated USA 0
NCT03601923 Phase II Niraparib Niraparib in Patients With Pancreatic Cancer Active, not recruiting USA 0
NCT03611556 Phase Ib/II Gemcitabine + Nab-paclitaxel + Oleclumab Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study Completed USA | NOR | ESP | AUS 0
NCT03649321 Phase Ib/II Cisplatin + Gemcitabine + Nab-paclitaxel Bemcentinib + Cisplatin + Gemcitabine + Nab-paclitaxel Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer Terminated USA 0
NCT03665441 Phase III Eryaspase + Gemcitabine + Nab-paclitaxel Eryaspase + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1) Completed USA | GBR | FRA 0
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Terminated USA | ESP | CAN | AUS 0
NCT03669601 Phase I Ceralasertib + Gemcitabine AZD6738 & Gemcitabine as Combination Therapy (ATRiUM) Unknown status GBR 0
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Active, not recruiting USA 0
NCT03697564 FDA approved Cabiralizumab + Gemcitabine + Nivolumab Gemcitabine Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). Suspended USA 0
NCT03699319 Phase II CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer Completed USA 0
NCT03721744 Phase II Gemcitabine + Napabucasin + Paclitaxel Fluorouracil + Liposomal irinotecan Gemcitabine Fluorouracil Capecitabine A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer Recruiting FRA | ESP 1
NCT03723915 Phase II Pelareorep + Pembrolizumab Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer Terminated USA 0
NCT03767582 Phase Ib/II BMS-813160 + GVAX pancreatic cancer vaccine + Nivolumab BMS-813160 + Nivolumab Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. Recruiting USA 0
NCT03801915 Phase II MVT-5873 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Completed USA 0
NCT03816163 Phase II Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + Zolbetuximab A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer Active, not recruiting USA | TUR | ITA | IRL | FRA | ESP | BRA | AUS 5
NCT03816358 Phase Ib/II Anetumab ravtansine + Gemcitabine + Nivolumab Anetumab ravtansine + Nivolumab Anetumab ravtansine + Ipilimumab + Nivolumab Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer Active, not recruiting USA | CAN 0
NCT03821935 Phase I ABBV-151 ABBV-151 + Budigalimab Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | ISR | FRA | ESP | CAN | BEL | AUS 4
NCT03851614 Phase II Cediranib + Durvalumab Durvalumab + Olaparib Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) Active, not recruiting CAN 0
NCT03854110 Phase Ib/II Gemcitabine + GP-2250 GP-2250 Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine Recruiting USA 0
NCT03872206 Phase Ib/II HPN536 Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Completed USA 0
NCT03891979 FDA approved Ciprofloxacin Metronidazole Pembrolizumab Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn USA 0
NCT03948763 Phase I mRNA 5671 mRNA 5671 + Pembrolizumab A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Completed USA | NZL | AUS 4
NCT03956056 Phase I Neoantigen peptide vaccine + Poly ICLC Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Terminated USA 0
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Terminated USA 0
NCT03970252 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer Completed USA 0
NCT04005690 Phase II Olaparib Cobimetinib Cobimetinib or Olaparib in Treating Patients With Resectable Pancreatic Cancer Recruiting USA 0
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting USA 0
NCT04034238 Phase I LMB-100 + Tofacitinib Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed USA 0
NCT04050085 Phase I Nivolumab + SD-101 SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer Completed USA 0
NCT04058964 Phase II PEGPH20 + Pembrolizumab Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer Withdrawn USA 0
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA | GBR 0
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Completed USA 0
NCT04083651 Phase II Methylnaltrexone Bromide A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer Withdrawn USA 0
NCT04098081 Phase II Galeterone + Gemcitabine Galeterone 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Recruiting USA 0
NCT04104672 Phase I AB680 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Recruiting USA 0
NCT04123574 Phase I Talabostat mesylate A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Withdrawn USA 0
NCT04132505 Phase I Binimetinib + Hydroxychloroquine Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer Active, not recruiting USA 0
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Completed USA | FRA | ESP | DEU | BEL 3
NCT04137536 Phase I EGFRBi-armed autologous activated T cells A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Active, not recruiting USA 0
NCT04152499 Phase Ib/II SKB264 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Recruiting USA | TUR | CAN 2
NCT04156087 Phase II Durvalumab + Gemcitabine + Tremelimumab Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC) Completed BEL 0
NCT04157127 Phase I DC tumor cell lysate vaccine Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (DECIST) Active, not recruiting USA 0
NCT04172532 Phase Ib/II Peposertib Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer Recruiting USA 0
NCT04191421 Phase Ib/II Siltuximab + Spartalizumab Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Completed USA 0
NCT04193904 Phase I MRx0518 A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer Terminated USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04214418 Phase Ib/II Atezolizumab + Cobimetinib + Hydroxychloroquine Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) Active, not recruiting USA 0
NCT04292743 Phase I Eryaspase + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT04327986 Phase Ib/II Bintrafusp alfa + NHS-IL12 Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer Terminated USA 0
NCT04331041 Phase II Defactinib Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma Recruiting USA 0
NCT04348045 Phase II Durvalumab + Selumetinib Fluorouracil + Irinotecan + Leucovorin Olaparib Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. (MAZEPPA) Active, not recruiting FRA 0
NCT04361162 Phase II Ipilimumab + Nivolumab Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer Active, not recruiting USA 0
NCT04386057 Phase II Hydroxychloroquine + LY3214996 LY3214996 LY3214996 +/- HCQ in Pancreatic Cancer Completed USA 0
NCT04387071 Phase Ib/II INCAGN01949 + Vidutolimod CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma Terminated USA 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP | CHE 1
NCT04390763 Phase II Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + NIS793 + Spartalizumab Gemcitabine + Nab-paclitaxel + NIS793 Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1) Terminated USA | ITA | GBR | FRA | FIN | ESP | DEU | CZE | CHE | BEL | AUT | AUS 2
NCT04393298 Phase Ib/II UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors Completed USA | GBR 0
NCT04404595 Phase Ib/II Satricabtagene autoleucel Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers Active, not recruiting USA | CAN 0
NCT04409002 Phase II Dostarlimab-gxly + Niraparib Niraparib + Dostarlimab + RT in Pancreatic Cancer Completed USA 0
NCT04431258 Phase Ib/II ABTL0812 + Fluorouracil + Irinotecan + Oxaliplatin Fluorouracil + Irinotecan + Oxaliplatin ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP) Completed USA | ISR | FRA | ESP 0
NCT04514497 Phase I Elimusertib + Irinotecan Elimusertib + Topotecan Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Active, not recruiting USA 0
NCT04543071 Phase II BKT140 + Cemiplimab + Gemcitabine + Nab-paclitaxel Chemo4METPANC Combination Chemotherapy in Patients With Pancreatic Adenocarcinoma Recruiting USA 0
NCT04548752 Phase II Olaparib + Pembrolizumab Olaparib Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations Recruiting USA 0
NCT04616534 Phase I Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Active, not recruiting USA 0
NCT04666740 Phase II Olaparib + Pembrolizumab A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy Active, not recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04683939 Phase Ib/II BNT141 BNT141 + Gemcitabine + Nab-paclitaxel Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors Terminated USA | CAN 0
NCT04731467 Phase Ib/II CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Active, not recruiting USA | ISR | ESP 0
NCT04787991 Phase I Gemcitabine + Ipilimumab + Nab-paclitaxel + Nivolumab Gemcitabine + Hydroxychloroquine + Ipilimumab + Nab-paclitaxel Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION) Active, not recruiting USA 0
NCT04807972 Phase II ABBV-927 + Budigalimab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin ABBV-927 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis Terminated USA | ISR | ESP | AUS 2
NCT04820179 Phase II Atezolizumab + Cabozantinib Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer Recruiting USA 0
NCT04825288 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + XB2001 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (1-BETTER) Completed USA 0
NCT04827953 Phase Ib/II Gemcitabine + Nab-paclitaxel + NLM-001 + Zalifrelimab Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 Before Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (NUMANTIA) Active, not recruiting ESP 0
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04940286 Phase II Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Active, not recruiting USA 0
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Recruiting USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS 4
NCT04983407 Phase Ib/II AVB-S6-500 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma Terminated USA 0
NCT04999969 Phase II AZD0171 + Durvalumab + Gemcitabine + Nab-paclitaxel Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours Active, not recruiting USA | ESP | CAN 1
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting USA 0
NCT05014776 Phase II CRS-207 + Ipilimumab + Pembrolizumab + Tadalafil A Phase 2 Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer Active, not recruiting USA 0
NCT05034627 Phase I Calaspargase pegol-mknl + Cobimetinib Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer Recruiting USA 0
NCT05057715 Phase I HuCART-meso cells + VCN-01 huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer Active, not recruiting USA 0
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05075564 Phase I ES002023 A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Unknown status USA 0
NCT05077800 Phase II Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Recruiting USA 0
NCT05088889 Phase I Ipilimumab + Nivolumab Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer Recruiting ISR 0
NCT05094336 Phase Ib/II AMG193 AMG193 + Docetaxel A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (MTAP) Recruiting USA | GBR | FRA | DEU | CHE | CAN | BEL | AUT | AUS 5
NCT05102721 Phase Ib/II Avelumab + Pepinemab Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma Recruiting USA 0
NCT05109442 Phase Ib/II AFM24 + Atezolizumab Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers Recruiting USA | POL | GBR | ESP 1
NCT05132504 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pembrolizumab Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer Recruiting USA 0
NCT05209074 Phase I Fluorouracil + Irinotecan + Ivosidenib + Leucovorin + Oxaliplatin Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Recruiting USA 0
NCT05212025 Phase II Adavosertib + Gemcitabine Adavosertib and Gemcitabine in Advanced Pancreatic Withdrawn 0
NCT05221320 Phase II Hydroxychloroquine + Ulixertinib Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Terminated USA 0
NCT05249101 Phase Ib/II Capecitabine Capecitabine + CG200745 A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma Recruiting USA 0
NCT05273554 Phase I Lenvatinib + Pembrolizumab A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT05355298 Phase Ib/II AMP945 AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer Recruiting AUS 1
NCT05365581 Phase I ASP2138 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin ASP2138 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab ASP2138 + Paclitaxel + Ramucirumab ASP2138 A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer Recruiting USA | ITA | FRA 3
NCT05394675 Phase I DS-9606a A Study of DS-9606a in Patients With Advanced Solid Tumors Recruiting USA | GBR 0
NCT05411133 Phase I ARB202 + Atezolizumab ARB202 Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients Recruiting AUS 1
NCT05417386 Phase I Fluorouracil + Irinotecan + Leucovorin + NIS793 + Oxaliplatin Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin FOLFIRINOX + NIS793 in Pancreatic Cancer Terminated USA 0
NCT05419479 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin AB154 + Sotigalimab + Zimberelimab Switch Maintenance in Pancreatic Recruiting USA 0
NCT05440942 Phase I Retifanlimab + Ruxolitinib + Trametinib Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT05451043 Phase II Cisplatin + Durvalumab + Gemcitabine + Propranolol + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Propranolol + Tremelimumab Durvalumab + Propranolol + Tremelimumab Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) Recruiting CAN 0
NCT05451849 Phase Ib/II Cyclophosphamide + Fludarabine TC-510 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA 0
NCT05462496 Phase II Ciprofloxacin + Fluorouracil + Irinotecan + Leucovorin + Metronidazole + Oxaliplatin + Pembrolizumab Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer Recruiting USA 0
NCT05482516 Phase III Atezolizumab + Bevacizumab Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) Recruiting USA 0
NCT05482893 Phase I PT886 PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) Recruiting USA 0
NCT05484011 Phase I CDX-1140 + PGG beta-glucan A Maintenance Therapy Study of Odetiglucan With a CD40 Agonist (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Terminated USA 0
NCT05494697 Phase II Rintatolimod Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma Recruiting USA 0
NCT05518110 Phase II Hydroxychloroquine + Trametinib PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer (PaTcH) Recruiting IRL 0
NCT05525286 Phase Ib/II Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + SOT102 Gemcitabine + Nab-paclitaxel + SOT102 SOT102 Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) Recruiting USA | FRA | ESP | CZE | BEL 0
NCT05539430 Phase I LB1908 Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma Recruiting USA 0
NCT05546411 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NIS793 + Oxaliplatin A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer Terminated USA 0
NCT05586516 Phase Ib/II Gemcitabine + IOA-289 + Nab-paclitaxel A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer Recruiting ITA | GBR 0
NCT05604560 Phase II SX-682 + Tislelizumab A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer Recruiting USA 0
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Active, not recruiting ESP | BEL 0
NCT05625412 Phase I CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | CAN | AUS | ARG 2
NCT05632328 Phase II Balstilimab + GS-1423 Balstilimab + Gemcitabine + GS-1423 + Nab-paclitaxel AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer Recruiting USA 0
NCT05646797 Phase I ASP2074 A Study of ASP2074 in Adults With Solid Tumors Terminated USA 1
NCT05659914 Phase II Durvalumab + Olaparib Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations Active, not recruiting ESP 0
NCT05673811 Phase II Gemcitabine + Nab-paclitaxel + VCN-01 Gemcitabine + Nab-paclitaxel Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer (VIRAGE) Active, not recruiting USA | ESP 0
NCT05685602 Phase I CA-4948 + Gemcitabine + Nab-paclitaxel CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer Recruiting USA 0
NCT05688215 Phase Ib/II AB680 + Irinotecan + Leucovorin + Oxaliplatin + Zimberelimab Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Recruiting USA 0
NCT05766748 Phase Ib/II Azeliragon Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer Recruiting USA 0
NCT05769959 Phase Ib/II RO7515629 Study of RO7515629 in Participants With HLA-G Positive Solid Tumors Terminated USA 0
NCT05795595 Phase Ib/II CTX131 A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors Recruiting USA 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DNK | CHE 1
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05848739 Phase I ST316 A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Recruiting USA 0
NCT05848843 Phase I Adagrasib + Durvalumab A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations Withdrawn USA 0
NCT05877599 Phase I NT-175 A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Recruiting USA 0
NCT05915351 Phase II Enfortumab vedotin-ejfv Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) Recruiting USA 0
NCT05919537 Phase Ib/II Docetaxel + HMBD-001 HMBD-001 Gemcitabine + HMBD-001 + Nab-paclitaxel Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Recruiting AUS 0
NCT05926206 Phase Ib/II CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas Withdrawn USA 0
NCT05985655 Phase Ib/II GTAEXS617 Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) Recruiting GBR | BEL 0
NCT05988918 Phase II CEP-11981 Multicenter Trial of ESK981 in Patients With Select Solid Tumors Recruiting USA 0
NCT06005493 Phase Ib/II AZD5863 Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors Recruiting USA | NLD | GBR | FRA 4
NCT06043713 Phase I Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations Recruiting USA 0
NCT06078787 Phase II Olaparib Olaparib in PALB2 Advanced Pancreatic Cancer (PALBOLA) Recruiting ITA 0
NCT06079346 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Trabedersen A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer (STOP-PC) Recruiting USA 0
NCT06094140 Phase II Durvalumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer (NEO-IMPACT) Active, not recruiting AUS 0
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA 2
NCT06199466 Phase I Gemcitabine + Nab-paclitaxel + YL-13027 A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer Active, not recruiting USA 0
NCT06208124 Phase Ib/II IMM-6-415 A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors Recruiting USA 0
NCT06217666 Phase I PCX12 Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) Not yet recruiting USA 0
NCT06218914 Phase I NT-112 A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation Recruiting USA 0
NCT06274437 Phase I BND-35 + Cetuximab BND-35 + Nivolumab BND-35 A Study of BND-35 in Participants With Advanced Solid Tumors Recruiting ISR 0
NCT06333314 Phase II Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) Recruiting FRA 0
NCT06360354 Phase I AMG193 + Cisplatin + Gemcitabine + Pembrolizumab AMG193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AMG193 + Gemcitabine + Nab-paclitaxel A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion Recruiting USA | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CAN | BEL | AUS 2
NCT06387342 Phase II CF102 Namodenoson Treatment of Advanced Pancreatic Cancer Not yet recruiting ISR 0
NCT06396091 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Zolbetuximab A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer Recruiting USA 0
NCT06398587 Phase II Gemcitabine + Nab-paclitaxel + Onvansertib Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Withdrawn USA 0
NCT06399757 Phase Ib/II APL-5125 A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors Recruiting USA 0
NCT06466187 Phase I SGN-MesoC2 A Study of SGN-MesoC2 in Advanced Solid Tumors Recruiting USA 0
NCT06483555 Phase Ib/II Erlotinib + Gemcitabine + Nab-paclitaxel Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel (PANGEA) Not yet recruiting USA 0
NCT06560632 Phase I Olaparib + RP-3467 RP-3467 Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR) Recruiting USA 0